Assessing uptake of the core outcome set in anxiety disorder clinical trials: a cross-sectional analysis

No abstract

Contributors

Jacob Duncan, Annes Elfar, Kimberly Magana, Garrett Jones, Shaelyn Ward, Trevor Magee, Jay Modi, Kyle Fitzgerald, Griffin Hughes, Alicia Ito Ford & Matt Vassar

Publication

Journal: Quality of Life Research
Volume:
Issue:
Pages: -
Year: 2024
DOI: https://dx.doi.org/10.1007/s11136-024-03697-x

Further Study Information

Current Stage: Completed
Date:
Funding source(s): This study was not funded


Health Area

Disease Category: Mental health

Disease Name: Anxiety, Depression, Obsessive-compulsive disorder (OCD)

Target Population

Age Range: 14 - 100

Sex: Either

Nature of Intervention: Any

Stakeholders Involved

Study Type

- COS uptake study

Method(s)

- Systematic review

Using the Core Outcome Measures in Effectiveness Trials (COMET) Initiative, the AD COS was identified and selected for uptake analysis. The COMET Initiative is an organization dedicated to the advocation and expansion of the use of COSs, while also compiling published COSs in a publicly available database. Since we were assessing interventions within clinical trials, we restricted our search to phase III and IV trials. Additionally, the cut-off date for our included sample of trials was December 26, 2012, to establish a baseline of outcome measurements prior to COS publication. ClinicalTrials.gov, an electronic clinical trial registry database, was searched on June 26, 2023, to identify phase III/IV RCTs in AD. ClinicalTrials.gov automatically searches synonyms and similar key words for conditions and diseases. A list of these generated search terms can be found in Supplemental File A. The following search filters were used when searching ClinicalTrials.gov, “conditions: anxiety”, “study type: interventional studies”, “phase: 3 and 4”, “date: 12/26/2012 to 06/26/2023”, with no restrictions regarding recruitment status. We also searched the International Clinical Trial Registry Platform (ICTRP) in a similar manner.